Ads
related to: drugs used to treat cml pain
Search results
Results from the WOW.Com Content Network
Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). [5] [7] [8] Asciminib is a protein kinase inhibitor. [5] The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. [7]
Nilotinib, sold under the brand name Tasigna among others, is a anti-cancer medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [3] [7] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. [3] [7] [8] It is ...
Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). [3] Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). [3] It is taken by mouth. [3]
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. [4] It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor. [5]
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R , ABL , c-KIT , FLT3 , and PDGFR-β .
The treatment options for imatinib resistant or intolerant CML patients may include strategies such as increasing the dose of imatinib or the use of second-generation drugs. Escalation of imatinib-doses has shown to overcome some cases of primary resistance to imatinib, such as Bcr-Abl duplication, but the response is usually short acting. [ 2 ]
The American Cancer Society estimates that in 2014, about 5,980 new cases of chronic myeloid leukemia were diagnosed, and about 810 people died of the disease. This means that a little over 10% of all newly diagnosed leukemia cases will be chronic myeloid leukemia. The average risk of a person getting this disease is 1 in 588.
Nilotinib is used to treat chronic myelogenous leukemia (CML), a hematological malignancy. A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.
Ads
related to: drugs used to treat cml pain